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We have analysed the mechanism of action for induction of apoptosis by N-substituted benzamides using declopramide as a
lead compound. We show here that declopramide at doses above 250 mM in the mouse 70Z/3 pre-B cell line or in the
human promyeolocytic cancer cell line HL60 induced cytochrome c release into the cytosol and caspase-9 activation. The
broad spectrum caspase inhibitor zVADfmk and caspase-9 inhibitor zLEDHfmk inhibited apoptosis and improved cell viability
when administrated to cells 1 h before exposure to declopramide, whereas the caspase-8 inhibitor zIEDHfmk had less effect.
Also, the over expression of Bcl-2 by transfection in 70Z/3 cells inhibited declopramide-induced apoptosis. Prior to the
induction of apoptosis, a G2/M cell cycle block was induced by declopramide. The cell cycle block was also observed in the
presence of broad spectrum caspase inhibitor zVADfmk and in a transfectant expressing high levels of Bcl-2. Furthermore,
while p53 was induced in 70Z/3 cells by declopramide, neither the apoptotic mechanism nor the G2/M cell cycle block were
dependent on p53 activation since both effects were also seen in p53 deﬁcient HL60 cells after addition of declopramide.
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Generally, cell and tissue homeostasis are regulated by genes that
activate or suppress apoptosis, cell proliferation and differentiation
(Raff, 1992). During the last decade a bulk of evidence has been
assembled showing that apoptosis plays an essential roll in develop-
ment, immune function, autoimmunity and cancer (Hanahan and
Weinberg, 2000; Krammer, 2000; Meier et al, 2000). Likewise,
several reports identify apoptotic cell death as an important cellular
mechanism to be utilised in the treatment of tumours (Fisher,
1994; Reed, 1995; Houghton, 1999). Apoptosis is initiated by
diverse death stimuli activating distinct biochemical pathways that
converge into a common effector step, leading to cellular degrada-
tion (Cohen, 1997). The activation step can involve ligand
interactions such as binding of Fas-ligand or TNF-a (tumour
necrosis factor-a) to speciﬁc ectoplasmic death receptors belonging
to the TNFR super family (Ashkenazi and Dixit, 1998) or oxidative
stress and DNA damage induced by agents such as cisplatin or g-
radiation (Lowe et al, 1993; Henkels and Turchi, 1999). As a result
of the apoptotic stimulus, the caspase cascade should be activated
(Newton et al, 1998; Rich et al, 2000).
Caspases are a highly conserved cysteine protease family with
speciﬁcity for aspartic acid residues in their substrates (Thornberry
et al, 1997). The activation of the caspase cascade involves both the
triggering as well as the ﬁnal stages of apoptosis (i.e. the execution
phase), and results in enzymatic cleavage of certain key substrates
eventually leading to apoptotic-/programmed cell death (Thornber-
ry, 1999; Hengartner, 2000). Two major triggering pathways have
been deﬁned for the caspase cascade. Mitochondria-mediated
apoptosis involves the release of cytochrome c which binds to
the Apaf-1 protein in the cytosol. This complex associates with
procaspase-9 and forms the apoptosome (Beere et al, 2000), which
in turn results in the activation of caspase-9 (Slee et al, 1999) and a
subsequent activation of effector caspases -3, -6 and -7 (Hakem et
al, 1998; Kuida et al, 1998; Thornberry, 1999). The Bcl-2 protein
family are important regulators of caspase-9 activation, where the
Bcl-2/Bax ratio in the mitochondria modulate the level of cyto-
chrome c release after apoptotic stimuli (Adams and Cory, 1998;
Hengartner, 2000). The other major apoptotic pathway important
in immune cell homeostasis and autoimmunity, involve activation
of caspase-8 via the death receptors localized on the cell surface
and their interaction with FAAD (Fas associated death domain
protein) (Juin and Evan, 2000). Once activated, caspase-8 can
directly activate the effector caspases -3, -6 and -7 (Ashkenazi
and Dixit, 1998). Also, as in the case of B cell receptor induced
apoptosis, caspase-8 can induce apoptosis by processing the Bid
protein into its truncated form that in turn can cause cytochrome
c release from the mitochondria and consequently caspase-9 activa-
tion (Berard et al, 1999).
The N-substituted benzamide metoclopramide (MCA, neu-
sensamide) and the structural analogue 3-chloroprocainamide
(3CPA, declopramide) have recently been identiﬁed as compounds
able to induce apoptosis in vitro (Pero et al, 1998; Liberg et al,
1999), and to have anti-inﬂammatory effects by inhibiting NFkB
(nuclear factor kappa B) activity (Liberg et al, 1999) and TNFa
production (Pero et al, 1999). Moreover, MCA and 3CPA have
earlier been shown to have radio- and chemo-sensitising properties
in vivo in murine and human tumour models (Kjellen et al, 1989,
1995; Olsson et al, 1997). 3CPA in combination with 5-FU (5-
ﬂourouracil) or cisplatin has recently completed phase-1 studies
in patients with advanced stage cancers. At dose escalations up
to total daily doses of 800 mg kg
71 alone or in combination with
5-FU, declopramide was considered safe and indicated efﬁcacy.
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sensitizer or as an anti-inﬂammatory agent, we further investigated
the mechanism of action of N-substituted benzamides. We were
able to demonstrate that these compounds induced a p53 indepen-
dent G2/M cell cycle block and apoptotic cell death involving the
mitochondrial pathway.
MATERIALS AND METHODS
Chemicals
Metoclopramide (MCA; neu-sensamide, metoclopramide hydro-
chloride monohydrate) and 3-chloroprocainamide (3CPA;
declopramide, 3-chloroprocainamide hydrochloride) were custom
synthesized by Oxigene Europe AB (Lund, Sweden) and prepared
as hydrochloride salt solutions in phosphate buffered NaCl (0.9%).
Etoposide, cytochrome c, RNaseA, proteinase K, polybrene, PI
(propidium iodide), 7AAD (7-amino-actinomycin D), and Nonidet
P-40 were all purchased from Sigma-Aldrich Company (St. Louis,
MO, USA). Z-VAD-fmk (benzyloxycarbonyl-Val-Ala-Asp-CH2F)
was from Promega (Madison, WI, USA), Z-IETD-fmk (benzyloxy-
carbonyl-Ile-Glu(OMe)-Thr-Asp(OMe)-CH2F) and Z-LEHD-fmk
(benzyloxycarbonyl-Leu-Glu(OMe)-His-Asp(OMe)-CH2F) were
purchased from Calbiochem-NovaBiochem Corp. (Bad Soden,
Germany), and Annexin V from Molecular Probes (Leiden, The
Netherlands).
Cells, transfection, and cell culturing
Human promyelocytic leukemia HL60 cells were maintained at
378C, 5% CO2 and 80% humidity. The cell density was between
2 and 9610
5 cells per ml in RPMI 1640 medium supplemented
with 10% foetal calf serum, gentamycin (50 mgm l
71), glutamine
(2 mM), Na-pyruvate (2 mM), and HEPES-buffer (20 mM) (R-10
medium). The murine pre-B-cell line 70Z/3 was maintained
under the same growth conditions, but the R-10 medium was
complemented with 50 mM mercapto-ethanol. 70Z/3 cells were
stably transfected with cDNA for mouse Bcl-2 (70Z/3
Bcl-2+),
inserted into a puromycin resistant mouse retro-virus vector
(pBabe Puro Bcl-2 plasmid). The transfection was performed
by incubation of cells with virus-containing supernatant in the
presence of polybrene (4 mgm l
71, Sigma). Further cloning was
performed with limiting dilution under selection by
0.75 mgm l
71 puromycin.
For apoptosis and ﬂow cytometry experiments the cell density
was adjusted to 2 to 5610
5 cells per well (HL60) or 2610
5 cells
per well (70Z/3) at the day before the experiment.
Flow cytometry
Apoptosis was measured by ﬂow cytometry (FACScan
1, Becton
Dickinson, USA), and apoptotic cells were identiﬁed as cells that
excluded the vital dye 7-amino-actinomycin D (7AAD
7)o r
propidium iodide (PI
7; Trevigen) but were positive to Annexin
V (Alexa Flour 488) (Liberg et al, 1999). Annexin V recognize
phosphatidyl serine moieties on the cell surface of apoptotic cells
(Koopman et al, 1994). Drug-induced effects on the cell cycle
was determined on cells prepared for ﬂow cytometry analysis
by labelling cells with propidium iodide according to Kallberg
and Leanderson (1995). Flow cytometry analysis was performed
after propidium iodide staining by incubation of cells for
30 min with Vindelo ¨vs low salt solution (3.4 mM Tris/HCl
pH 7.6, 75 mM propidium iodide, 0.1% NP40, 10 mM NaCl)
prior to analysis. The analysis was performed with a FACScan
1
analyzer (Becton Dickinson), where DNA content and grade of
DNA fragmentation (apoptosis appearing as a sub-G1 fraction),
and distribution of cells in G1,G 2/M or S-phase, was deter-
mined.
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Figure 1 Induction of apoptosis in 70Z/3 cells treated with 3CPA at
250 mM and 500 mM.( A) Cytochrome c release into the cytosol after ex-
posure to 3CPA for indicated time periods measured by Western blot ana-
lysis. (B) Pro-caspase-9 processing determined in cytosolic fractions after
exposure to 3CPA. Actin was used as an internal standard of the protein
load and the results shown are representatives of two separate experi-
ments. (C) Caspase inhibitors reduce 3CPA-induced apoptosis in 70Z/3
cells. Apoptosis, measured as AnnexinV
+7AAD
7 cells, was determined
after exposure to 3CPA at 250 mM (left) and 500 mM (right) for 24 h.
The pan-caspase inhibitor ZVAD-fmk (50 mM, n=4), the caspase-9 inhibitor
LEHD-fmk (50 mM, n=3), or the caspase-8 inhibitor IETD-fmk (50 mM, n=3)
were added 1 h before treatment with 3CPA. The level of apoptosis is ex-
pressed relative to the level in cell cultures treated with the inhibitor only.
Results show mean+s.d., and (*) indicates a statistical difference compared
to 3CPA only (paired t-test, P50.05).
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SDS–PAGE and Western blot analysis was performed on the
10000 g supernatant fraction from total soluble proteins (Wang
et al, 1998), or on cytosolic and mitochondrial fractions prepared
from HL60 and 70Z/3 cells. Mitochondria enriched fractions were
prepared by 60 s of gentle homogenisation with a plastic Eppen-
dorf pestle in an Eppendorf tube (100 ml cell suspension
representing 5610
6 cells suspended in homogenising buffer;
HEPES-KOH 20 mM, pH 7.5, 10 mM KCl, EDTA 1 mM, EGTA
1m M, DTT 1 mM, PMSF 0.1 mM and sucrose 250 mM) (Yang et
al, 1997) before centrifugation at 700 g. This was followed by a
second centrifugation at 10000 g to separate the mitochondria
from the cytosol fraction. Electrophoresis was performed on a
12% polyacrylamide gel (150 V per 60 mA). Equal amounts of
protein (30–60 mg) were loaded in each lane. Protein transfer to
a nylon membrane (Hybond-C Extra; Amersham, UK) was
performed at 15 V per 200 mA for 30 min. After blocking over-
night in 5% dry fat-free milk in TBST (10 mM Tris-HCl, pH 8,
150 mM NaCl, 0.05% Tween-20), incubation with a primary anti-
body for 2 h was performed. Cytochrome c was detected using a
cytochrome c antibody (mouse IgG2b, clone 7H8.2C12; Pharmin-
gen). To detect pro-caspase-9 or active caspase-9, a rabbit
polyclonal anti-mouse caspase-9 (Santa Cruz) or a rabbit polyclo-
nal anti-human caspase-9 (Pharmingen) was used. The Bcl-2
antibody was purchased from Pharmingen, anti-actin from Sigma,
the rabbit polyclonal anti-mouse-p53 antibody (NCL-p53-CM5p)
was purchased from Novocastra Laboratories (UK) and the anti-
human/-mouse p53 (mouse monoclonal IgG1, Pab 240) was from
Santa Cruz. After washing in TBST incubation with either a
secondary (HRP)-conjugated anti-mouse, -rabbit or -goat antibody
(Santa Cruz) was performed, followed by chemiluminescence ECL-
reagent (Amersham).
RESULTS
3CPA-induced apoptosis correlates with cytochrome c
release and caspase-9 activation
We have reported earlier that the N-substituted benzamides meto-
clopramide (MCA) and declopramide (3CPA) have the ability to
induce apoptosis in target cells such as murine 70Z/3 and human
HL60 cells in vitro (Pero et al, 1998; Liberg et al, 1999). To further
deﬁne the cytotoxic mechanism of N-substituted benzamides, we
expanded our previous studies using the murine 70Z/3 pre-B cell
line as the in vitro model (Liberg et al, 1999) and 3CPA as the
active moiety. The common apoptotic pathway leading to drug-
induced apoptosis is preceded by a disruption of the mitochondrial
trans-membrane potential, followed by cytochrome c release into
the cytosol and activation of caspase-9 (Houghton, 1999; Kroemer
and Reed, 2000).
For that reason, we performed Western blot analysis of cytosol
preparations from 70Z/3 cells exposed to 3CPA. Cytochrome c
release into the cytosol could be detected after 12 h incubation
with 3CPA (Figure 1A). The lack of detectable cytochrome c in
cytosol fractions from unexposed cell cultures, was taken as
evidence that no leakage from the mitochondria due to bad
preparation procedure occurred (Figure 1A). Processing of procas-
pase-9 into active caspase-9, as detected by the disappearance of
the 48 kD procaspase-9 band in conjunction with the appearance
of a band at 10 kD, was seen after 12–18 h (Figure 1B). Moreover,
the addition of 3CPA (250 and 500 mM) to 70Z/3 cells, induced an
increase of apoptotic cells above background as detected by Annex-
in V
+7AAD
7 staining after 6–12 h. The fraction of early apoptotic
cells reached a steady state level of 10–15% Annexin V
+7AAD
7
cells after 18–24 h (data not shown). As shown in Figure 1C,
co-administration for 24 h of the pan-caspase inhibitor Z-VAD-
fmk (50 mM) signiﬁcantly reduced the fraction of Annexin
V
+7AAD
7 cells (P50.05, paired t-test, n=4). The caspase-9 inhibi-
tor Z-LEHD-fmk (50 mM) also signiﬁcantly inhibited 3CPA-
induced apoptosis (P50.05, paired t-test, n=3), whereas addition
of the caspase-8 inhibitor Z-IETD-fmk (50 mM) (Thornberry et
al, 1997; Garcia-Calvo et al, 1998) had less effect (P40.1, paired
t-test, n=3) (Figure 1C). We concluded from these experiments
that the cytotoxic function of N-substituted benzamides required
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
A
18%
85%
Gate A
35%
4%
Annexin V
70Z/3
Bcl-2+
7AAD
70Z/3
3CPA:       0        250       500         0         250        500     µM
Bcl-2
Cytochrome C
Actin
Pro-caspase 9
Caspase 9
Actin
A
70Z/3
B
C
A
70Z/3Bcl-2+
Figure 2 Over-expression of Bcl-2 in 70Z/3 cells inhibits 3CPA-induced
apoptosis. (A) FACS-analysis of 70Z/3 (upper panel) and 70Z/3
Bcl-2+ (low-
er panel) cells after exposure to 3CPA (500 mM) for 18 h. 7AAD negative
(viable) cells were gated (gate A) and analysed for Annexin V
+ expression
(% of gated cells). (B) Levels of Bcl-2 and cytochrome c expression were
determined by Western blot analysis in mitochondrial enriched fractions
after 18 h incubation with 3CPA at the indicated concentrations (30 mg
protein per lane). (C) Pro-caspase-9 processing into active caspase-9
was determined in the cytosolic fraction after 18 h incubation with
3CPA at the indicated concentrations. Actin was used as an internal stan-
dard to control the amount of cytosolic protein loaded in each lane. Results
shown are representatives of two independent experiments.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(6), 971–978a functional caspase-9 activation pathway, although the involve-
ment of caspase-8 activity in 3CPA-induced apoptosis could not
be totally excluded.
Cytochrome c release and caspase-9 activation are inhibited
by the over-expression of Bcl-2
Cytochrome c release and caspase-9 activation are to some extent
regulated by members of the Bcl-2 protein family, which are asso-
ciated with the exterior mitochondria membrane. The
mitochondrial trans-membrane potential, and thereby membrane
integrity, is at least in part regulated by the ratio between the
anti-apoptotic Bcl-2 family proteins Bcl-2 and Bcl-XL and the
pro-apoptotic proteins Bax and Bad (Oltvai et al, 1993). Thus,
to study the inﬂuence of Bcl-2 on 3CPA-induced apoptosis,
70Z/3 cells were transfected with a Bcl-2 expression vector and
a stable 70Z/3
Bcl-2+ cell line was established. As shown in Figure
2A, treatment with 3CPA at a dose of 500 mM did not induce
apoptosis or cyto-toxicity to the same extent in 70Z/3
Bcl-2+ cells
as in wild-type 70Z/3 cells. Furthermore, Western blot analysis
showed that Bcl-2 levels in the mitochondria-enriched fraction
remained on an equally high level independently of dose in
70Z/3
Bcl-2+ cells. In contrast, the Bcl-2 levels tended to decline
in the mitochondria-enriched fraction of wild-type 70Z/3 cells
treated with 500 mM 3CPA for 18 h (Figure 2B). Also, release of
cytochrome c from mitochondria and caspase-9 activation was
seen after 18 h 3CPA treatment in 70Z/3 cells but was not
observed after treatment of 70Z/3
Bcl–2+ cells (Figure 2B,C). These
experiments strongly suggested that N-substituted benzamides
induced an apoptotic response via a mechanism involving the
mitochondrial pathway.
3CPA treatment induce a G2/M cell cycle block in 70Z/3
cells
Drug-induced apoptosis via cytochrome c release and caspase-9
activation often involve upstream events associated to oxidative
stress and DNA damage (Beere et al, 2000; Rich et al, 2000). More-
over, cell cycle regulatory events resulting in cell cycle arrest and
mitochondria-associated apoptosis can be mediated by a number
of cellular signalling pathways. In order to investigate if 3CPA
affected the cell cycle we analysed the cell cycle distribution of
70Z/3 cells after 3CPA treatment. As shown in Figure 3A, an
increased fraction of cells in G2/M-phase was seen already after
6 h incubation with 500 mM 3CPA, followed by apoptosis and
the formation of a sub-G1 fraction after 12–24 h. Thus, an accu-
mulation of cells in G2/M-phase occurred prior to apoptosis as
detected by the accumulation of a sub-G1 population.
Next we wanted to establish that the increased fraction of cells
in G2/M-phase after exposure to 3CPA was a true cell cycle block
and not just due to the fact that cells in this phase were protected
from cell death whereas cells in G0/G1/S-phase were not. Further-
more, we wanted to investigate whether caspase activation was
needed for the establishment of the G2/M-phase blockade. To this
end, we added the caspase inhibitor ZVAD-fmk (50 mM) together
with 3CPA (500 mM) to 70Z/3 cells and performed cell cycle analy-
sis after 24 h of incubation (see Figure 3A for kinetics of the G2/M
blockade). As shown in Figure 3B, over 50% of the events in the
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Figure 3 3CPA induces cell cycle block in the G2/M-phase in 70Z/3 cells independent of caspase activity. (A) 70Z/3 cells were exposed for 3CPA at
500 mM for 6 to 18 h whereafter cells in different cell cycle phases were determined by ﬂow cytometry analysis of propidium iodide labelled cells (Kallberg
and Leanderson, 1995). Indicated numbers in the ﬁgure show the sub-G1 fraction expressed as percent of total events. (B) ZVAD-fmk (50 mM) prevents
70Z/3 cells to undergo apoptosis after 24 h of exposure to 500 mM 3CPA and allow cells to accumulate in G2/M-phase. Addition of ZVAD-fmk only had no
effect on cell cycle distribution (data not shown). (C) Cell cycle arrest in G2/M phase occurs regardless of the inhibition of apoptosis in 70Z/3
Bcl-2+ cells after
12 h exposure to 500 mM 3CPA. One out of two representative experiments is shown.
N-substituted benzamide-induced apoptosis
AR Olsson et al
974
British Journal of Cancer (2002) 86(6), 971–978 ã 2002 Cancer Research UKcontrol cultures were in the sub-G1 fraction and the remaining
population more or less evenly spread throughout the cell cycle.
However, in ZVAD-fmk treated cultures only 10% of the events
were in the sub-G1-region and the G2/M block was still easily
observed after 24 h of incubation. Furthermore, 3CPA treatment
of 70Z/3
Bcl-2+ cells also induced a G2/M block even though induc-
tion of apoptosis in this cell line was marginal after 12 h showing
that Bcl-2 does not affect the G2/M block (Figure 3C). Thus, we
concluded that 3CPA treatment induced a cell cycle block in the
G2/M-phase of the cell cycle, and the establishment of this cell cycle
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Figure 4 3CPA induces p53 in 70Z/3 cells but not in HL60 cells. (A)
p53 expression in mouse 70Z/3 cells after incubation with 3CPA at
250 mM or 500 mM. p53 expression in the cytosol was detected by the rab-
bit polyclonal anti-mouse-p53 antibody (NCL-p53-CM5p; Novocastra La-
boratories) (40 mg protein/lane). (B) Lack of p53 protein expression in
HL60 cells exposed to 250 or 500 mM 3CPA for 12 h. p53 in the cytosol
was detected by the mouse monoclonal anti-human/-mouse p53 antibody
(Santa Cruz, sc-240). Human HeLa cells exposed to 500 mM 3CPA were
included as a positive control and equal amount of protein (47 mg) was
loaded.
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Figure 5 3CPA-induced apoptosis in p53-negative HL60 cells. Apopto-
sis was determined as percent AnnexinV
+PI
- cells of total cells in culture,
after exposure to 3CPA at 250 and 500 mM for 18 h. The level of apoptosis
was reduced by pre-incubation with the pan-caspase inhibitor ZVAD-fmk
(50 mM) for 1 h before addition of 3CPA. Bar-graphs represent the
average+s.d. of three independent experiments, and (*) indicates a statis-
tical difference compared to 3CPA only (paired t-test, P50.05).
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Figure 6 N-substituted benzamides induce cytochrome c release and activation of caspase-9 in HL60 cells. (A) Cytochrome c release induced by MCA
(500 mM) and 3CPA (250 mM) in HL60 cells after 24 and 48 h, measured by Western blot analysis of mitochondria or cytosol fractions (30 mg protein/lane).
Cells were incubated with etoposide for 6 and 18 h at 100 mM as a positive control. (B) Activation of caspase-9 after treatment of HL60 cells with 3CPA at
250 and 500 mM for 12 and 18 h (48 mg protein per lane). One representative experiment out of two is shown.
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On the other hand, the G2/M block did not cause apoptosis by
itself but seemed to need a functional mitochondria-mediated
caspase pathway down-stream. Thus, if the cell cycle block is a trig-
ger of caspase activation or if the two are independent events
remains to be established.
The induction of apoptosis by N-substituted benzamides is
not dependent of p53
A possible adjacent mediator between cell cycle arrest and apopto-
sis is the nuclear p53 protein. p53 is up-regulated by DNA damage
and has been shown to be associated with cell cycle block both in
G0/G1- and G2/M-phase depending on the nature of damage, dose
and cell type (Lu and Lane, 1993). We therefore investigated the
possible effect of 3CPA on p53-expression by Western blot analysis
of cell extracts from 70Z/3 cells exposed to 250 or 500 mM 3CPA
for 12–24 h. As shown in Figure 4A, a substantial up-regulation
of p53 was detected in the mitochondria-enriched fraction at
12 h, and the elevated p53 levels declined with time to slightly
above the control level after 24 h. The data suggested that 3CPA-
induced G2/M blockade might involve the p53-signalling pathway.
For that reason, we decided to expand our studies to the p53 deﬁ-
cient HL60 cell line in which we could directly analyse whether
both the ability of N-substituted benzamides to induce apoptosis
and G2/M arrest were dependent on p53 signalling.
As expected, we were not able to detect p53 expression in
human leukaemic HL60 cells after treatment with 3CPA, since
HL60 cells are known to lack a functional p53 pathway (Danova
et al, 1990) (Figure 4B). However, when HL60 cells were exposed
to 3CPA, an apoptotic cell fraction was observed by FACS analysis
(Annexin V
+PI
7 cells), showing that the ability of this compound
to induce apoptosis was not requiring a functional p53 in this cell
line (Figure 5). The apoptotic cells appeared in culture 12–18 h
after the compounds were added, which was consistent with earlier
data obtained in HL60 cells (Pero et al, 1998), and the induction of
apoptosis was inhibited by the presence of ZVAD-fmk at 50 mM
(Figure 5). Also, cytochrome c release from the mitochondria to
the cytosol was detected after treatment of HL60 cells with 3CPA
or MCA (Figure 6A). In conjunction with cytochrome c release
after 12 h (data not shown), procaspase-9 was processed into its
active form caspase-9 after 12–18 h when exposed to 3CPA at
doses of 250 and 500 mM at 24–48 h (Figure 6B). Thus, we
conclude from these results that N-substituted benzamides can
induce apoptosis via a p53-independent mechanism.
Lastly we analysed the effect of 3CPA addition on the cell cycle
distribution of HL60 cells. As shown in Figure 7A, a G2/M block
was easily detectable in 3CPA-treated cultures. The accumulation
of cells in G2/M-phase took place before cells expressed phosphati-
dyl serine on their cell surface (Annexin V
+7AAD
7 cells) and
appeared as a sub-G1 population with less DNA than viable G0/
G1-cells (Figure 7B). Hence, also the effect on cell cycle distribution
after 3CPA treatment can be established in the absence of p53.
DISCUSSION
The N-substituted benzamides have been shown to have multiple
modes of biological activity, because they: (i) have D2- and 5-
HT3-receptor binding afﬁnity (Harrington et al, 1983); (ii) induce
apoptosis and inhibit proliferation in vitro (Pero et al, 1998; Liberg
et al, 1999); (iii) sensitise low dose radiation and delay in vivo
tumour growth (Hua and Pero, 1997; Olsson et al, 1997); (iv) have
anti-inﬂammatory properties by inhibiting NFkB activity in human
Jurkat T-cells (Lindgren et al, 2001) and mouse pre-B 70Z/3 cells
(Liberg et al, 1999) and ﬁnally; (v) inhibit TNFa production in
vitro as well as in vivo (Pero et al, 1999). To eliminate species
speciﬁc responses we have utilised two different haematopoetic cell
lines, 70Z/3 mouse pre-B-cells and human HL60 promyelocytic
leukaemia cells, to study the mechanism of apoptosis induced by
N-substituted benzamides. These cell lines differ in origin and they
have several distinct differences in gene expression and function.
Anticancer drug-induced apoptosis has been shown to depend on
intact caspase cascades (Li et al, 1997; Ferrari et al, 1998). In the
current investigation the pan-caspase inhibitor ZVAD-fmk inhib-
ited apoptosis induced by 3CPA both in 70Z/3 and HL60 cells
(Figures 1C and 5). Furthermore, the speciﬁc caspase-9 inhibitor
LEDH-fmk (Thornberry et al, 1997; Garcia-Calvo et al, 1998;
Komoriya et al, 2000) inhibited apoptosis almost at the same level
(30–50% inhibition), while the speciﬁc caspase-8 inhibitor IETD-
fmk (Thornberry et al, 1997; Komoriya et al, 2000) showed less
inhibitory effect on 3CPA-induced apoptosis (Figure 1C). The data
suggest to us that caspase-9 is the initiator caspase involved in
3CPA-induced apoptosis. The conclusion is further supported by
the observation that the addition of 3CPA induces cytochrome c
release to the cytosol and caspase-9 activation. Hence, we believe
that we have deﬁned an apoptotic pathway involved in N-substi-
tuted benzamide-induced apoptosis.
Another interesting observation in this study is the distinct G2/
M cell cycle block induced by 3CPA. By using caspase inhibitors
and a Bcl-2 transfectant cell line we could demonstrate that this
cell cycle arrest is an event occurring prior to 3CPA-induced apop-
tosis. It is well documented that DNA damage induced by g-
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Figure 7 3CPA-induces apoptosis and cell cycle block in human HL60
cells. (A) Cell cycle distribution in HL60 cells exposed to 500 mM 3CPA
for 24 h. Cells in different cell cycle phases were determined by ﬂow cyto-
metry analysis of propidium iodide labelled cells. Indicated numbers in the
ﬁgure show the sub-G1 fraction expressed as percent of total events. (B)
The accumulation of HL60 cells in G2/M-phase appears before apoptosis is
induced. HL60 cells were incubated with 500 mM 3CPA for indicated time
points before cell cycle analysis and apoptosis was measured. Bars repre-
sent G2/M fractions expressed as % of total cells+s.d. in, (&) unexposed
cells and (&) cells exposed to 3CPA for indicated time periods. Apoptotic
cells were determined as Annexin
+7AAD
- cells (% of total cells+s.d.) not
exposed (–&–) or exposed (*) to 500 mM 3CPA for indicated time
periods.
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(Beere et al, 2000), chemicals such as glucocorticoids (Meng and
El-Deiry, 2001), cisplatin (O’Connor and Lu, 2000) or topoisome-
rase-2 inhibitors (Dubrez et al, 1995), cause cell cycle arrest in G0/
G1 or G2/M-phase prior to cell death via apoptosis. Whether any of
these routes to apoptotic cell death are activated by N-substituted
benzamides remains to be established.
It has been shown that DNA damage induced by ionising radia-
tion involves activation of p53, and can result in cell cycle arrest
both in the G1/G0-phase and in G2/M-phase in 70Z/3 cells
(Aloni-Grinstein et al, 1995). Indeed, in analogy with g-radiation,
we measured an up-regulation of p53 in 70Z/3 cells after treatment
with 3CPA (Figure 4A). However, it is not likely that p53 plays an
essential role in the apoptotic pathway activated by the N-substi-
tuted benzamides since apoptosis also was induced in the p53
deﬁcient HL60 cell line. Furthermore, a G2/M cell cycle block
was also observed in HL60 cells, arguing for the fact that the
benzamide-induced cell cycle block is established by signalling
pathways distinct from p53.
In conclusion, we have shown that N-substituted benzamides
can activate the caspase cascade via the mitochondrial pathway
and arrest cells in the G2/M phase. If the induction of apoptosis
by the N-substituted benzamides is dependent on cell cycle arrest
or not, is still not resolved and the connection between these
two events must be subject to further studies.
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